CHE Stock Analysis: Chemed | NYSE
Medical Care Facilities | NYSE, USA | Market Cap: 7.160m USD | 12M Return: 29.8% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 80.2M
EPS Trend: 34.6%
Qual. Beats: 2
Rev. Trend: 97.8%
Qual. Beats: 2
Warnings
Tailwinds
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Chemed Corporation operates two distinct business segments: VITAS Healthcare, which provides hospice and palliative care services through multidisciplinary teams of physicians, nurses, aides, social workers, clergy, and volunteers, and Roto-Rooter, which offers plumbing, drain cleaning, excavation, and water restoration services to residential and commercial customers via company-owned branches, independent contractors, and franchisees. The company is headquartered in Cincinnati, Ohio, was incorporated in 1970, and trades on the NYSE under the ticker CHE.
Chemeds business model is notable for its unusual pairing of a healthcare services segment with a home services franchise operation. U.S. hospice providers like VITAS are predominantly reimbursed through the Medicare Hospice Benefit, which subjects the segment to regulated per-diem payment rates, while Roto-Rooter generates revenue through a mix of direct operations and franchising.
- Medicare hospice reimbursement cuts pressure VITAS margins
- Roto-Rooter weather-driven demand boosts residential service revenue
- Share repurchases return capital as buyback authorization continues
| Net Income: 275.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.20 > 0.02 and ΔFCF/TA -1.13 > 1.0 |
| NWC/Revenue: -1.10% < 20% (prev 9.06%; Δ -10.16% < -1%) |
| CFO/TA 0.25 > 3% & CFO 390.0m > Net Income 275.0m |
| Net Debt (400.3m) to EBITDA (431.7m): 0.93 < 3 |
| Current Ratio: 0.91 > 1.5 & < 3 |
| Outstanding Shares: last quarter (13.4m) vs 12m ago -8.10% < -2% |
| Gross Margin: 30.44% > 18% (prev 33.65%; Δ -3.21% > 0.5%) |
| Asset Turnover: 157.4% > 50% (prev 146.2%; Δ 11.17% > 0%) |
| Interest Coverage Ratio: 75.74 > 6 (EBIT TTM 365.3m / Interest Expense TTM 4.82m) |
| A: -0.02 (Total Current Assets 291.2m - Total Current Liabilities 319.8m) / Total Assets 1.58b |
| B: 1.95 (Retained Earnings 3.07b / Total Assets 1.58b) |
| C: 0.22 (EBIT TTM 365.3m / Avg Total Assets 1.65b) |
| D: 1.11 (Book Value of Equity 830.5m / Total Liabilities 749.1m) |
| Altman-Z'' = 8.88 = AAA |
| DSRI: 0.99 (Receivables 188.6m/184.9m, Revenue 2.60b/2.51b) |
| GMI: 1.11 (GM 33.65% / 30.44%) |
| AQI: 1.40 (AQ_t 0.73 / AQ_t-1 0.52) |
| SGI: 1.03 (Revenue 2.60b / 2.51b) |
| TATA: -0.07 (NI 275.0m - CFO 390.0m) / TA 1.58b) |
| Beneish M = -2.69 (Cap -4..+1) = A |
As of August 01, 2026, the stock is trading at USD 532.25 with a total of 161,271 shares traded. Over the past week, the price has changed by +4.13%, over one month by +14.28%, over three months by +25.41% and over the past year by +29.79%.
Current recommended Stop Loss: 516.40 (which is 3% or 1.2 ATR below the current price).
Chemed has received a consensus analysts rating of 4.67. Therefore, it is recommended to buy CHE.
- StrongBuy: 2
- Buy: 1
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 474 | -10.9% |
P/E Trailing = 28.2535
P/E Forward = 21.2314
P/S = 2.8181
P/B = 8.1027
P/EG = 2.124
Revenue TTM = 2.60b USD
EBIT TTM = 365.3m USD
EBITDA TTM = 431.7m USD
Long Term Debt = 91.2m USD (from longTermDebt, two quarters ago)
Short Term Debt = 41.3m USD (from shortTermDebt, last quarter)
Debt = 440.5m USD (from shortLongTermDebtTotal, last quarter) + Leases 145.7m
Net Debt = 400.3m USD (calculated: Debt 440.5m - CCE 40.2m)
Enterprise Value = 7.56b USD (7.16b + Debt 440.5m - CCE 40.2m)
Interest Coverage Ratio = 75.74 (Ebit TTM 365.3m / Interest Expense TTM 4.82m)
EV/FCF = 23.36x (Enterprise Value 7.56b / FCF TTM 323.6m)
FCF Yield = 4.28% (FCF TTM 323.6m / Enterprise Value 7.56b)
FCF Margin = 12.47% (FCF TTM 323.6m / Revenue TTM 2.60b)
Net Margin = 10.60% (Net Income TTM 275.0m / Revenue TTM 2.60b)
Gross Margin = 30.44% ((Revenue TTM 2.60b - Cost of Revenue TTM 1.81b) / Revenue TTM)
Gross Margin QoQ = 30.36% (prev 30.25%)
Tobins Q-Ratio = 4.79 (Enterprise Value 7.56b / Total Assets 1.58b)
Interest Expense / Debt = 1.09% (Interest Expense 4.82m / Debt 440.5m)
Taxrate = 25.51% (94.2m / 369.2m)
NOPAT = 272.1m (EBIT 365.3m * (1 - 25.51%))
Current Ratio = 0.91 (Total Current Assets 291.2m / Total Current Liabilities 319.8m)
Debt / Equity = 0.53 (Debt 440.5m / totalStockholderEquity, last quarter 830.5m)
Debt / EBITDA = 0.93 (Net Debt 400.3m / EBITDA 431.7m)
Debt / FCF = 1.24 (Net Debt 400.3m / FCF TTM 323.6m)
Total Stockholder Equity = 933.6m (last 4 quarters mean from totalStockholderEquity)
RoA = 16.68% (Net Income 275.0m / Total Assets 1.58b)
RoE = 29.45% (Net Income TTM 275.0m / Total Stockholder Equity 933.6m)
RoCE = 35.64% (EBIT 365.3m / Capital Employed (Equity 933.6m + L.T.Debt 91.2m))
RoIC = 21.58% (NOPAT 272.1m / Invested Capital 1.26b)
WACC = 6.17% (E(7.16b)/V(7.60b) * Re(6.50%) + D(440.5m)/V(7.60b) * Rd(1.09%) * (1-Tc(0.26)))
Discount Rate = 6.50% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -97.21 | Cagr: -5.76%
[DCF] Terminal Value 73.48% ; FCFF base≈342.7m ; Y1≈306.8m ; Y5≈258.4m
[DCF] Fair Price = 280.6 (EV 4.13b - Net Debt 400.3m = Equity 3.73b / Shares 13.3m; r=8.35% [WACC [floored]]; 5y FCF grow -12.87% → 2.50% )
EPS Correlation: 34.61 | EPS CAGR: 1.61% | SUE: 1.11 | # QB: 2
Revenue Correlation: 97.79 | Revenue CAGR: 5.76% | SUE: 0.95 | # QB: 2
EPS current Quarter (2026-09-30): EPS=6.02 | Chg30d=+0.04% | Revisions=+0% | Analysts=4
EPS current Year (2026-12-31): EPS=24.34 | Chg30d=-0.04% | Revisions=-25% | GrowthEPS=+13.0% | GrowthRev=+6.4%
EPS next Year (2027-12-31): EPS=26.88 | Chg30d=-0.10% | Revisions=-25% | GrowthEPS=+10.4% | GrowthRev=+6.2%
[Analyst] Revisions Ratio: -29% (up=1, down=3)